Liquid Biopsy Market

Publisher: AnalystView Market Insights
Publication Date: June, 2020
Healthcare / Medical Equipment
Pages: 198
Delivery Format: PDF

by Sample Type (Urine Sample-based, and Blood Sample-based), By Technology (Multi-gene-parallel Analysis (NGS), and Single Gene Analysis (PCR Microarrays)), By Biomaker (ctDNA, CTC, and Exosomes), By Application, By Technology, and By Geography (NA, EU, APAC, LATAM and MEA) Ð Analysis, Share, Trends, Size, & Forecast From 2020 Ð 2026

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

REPORT HIGHLIGHT
Liquid biopsy Market was valued at USD 49.72 million by 2019, growing with 14.6% CAGR during the forecast period, 2020-2026
Market Dynamics
Liquid biopsy is a non-invasive and easy method used to diagnose onset of cancer. Liquid biopsy is also called as fluid phase biopsy or fluid biopsy. With liquid biopsy tumors and mutations can be easily tracked over a period of time. For cancer treatment, safety and efficiency is improved by the use of these tests because of their ability to predict treatment outcome, execute apt therapeutic targets, and characterize new lesions.
The growing number of patients being diagnosed with several types of cancer and the advantages of liquid biopsy such as metastatic relapse and minimally invasive are the major factors driving the growth of global liquid biopsy market. According to World Health Organization (WHO), cancer is the second leading cause of death all over the world. Around 9.6 million deaths in 2018 were due to various types of cancer. Moreover, minimally invasive therapies are highly preferred by patients and a surge in disposable income is also witnessed among cancer patients, which is anticipated to propel the market growth during the forecast period. In addition, an increase in healthcare expenditure in the emerging economies such as China and India and growing use of biopsy tests are likely to create lucrative opportunities in the global industry. However, unclear regulation & reimbursement scenario and availability of alternatives to liquid biopsies are predicted to restrict the market growth in the coming future.
Sample Type Takeaway
Blood sample-based is anticipated to grow at a significant rate during the forecast period owing to numerous methods for purification and preexisting applications. Microvesicles, exosomes, circulating tumor cells, and cell-free DNA can be detected in blood samples. In the saliva-based sample type, the next generation sequencing technology is used for detecting multiple mutations in multiple genes. As per certain studies plasma and saliva measurements are corelated, which potentially presents that detection of oncogenic gene mutations.
Biomarker Takeaway
CTC biomarkers segment is estimated to hold the largest market share in the forecast period owing to accurate tracking results and high awareness levels of cancerous cells in the human body. The number of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) based liquid biopsy tests that are commercialized are 8-10. The CTC tests are applicable through biochemical marker analysis for classification of tumor cells through. CTC detection, isolation, and molecular characterization systems find tentative application in pancreatic, prostate, colon, breast, head, skin, neck, and lung cancer.
Technology Takeaway
The multi-gene-parallel analysis (NGS) segment is expected to subjugate the worldwide market owing to its capability to denote diagnosis of multiple diseases at one time. Clinical pharmacogenomics tests are taken away by multigene tests from conventional sequencing of single genes, which is marked as a noteworthy step towards detailed analysis of cancer genome. This technology helps oncologists in guiding patients to the targeted therapy by detecting the genetic aberrations. On the other hand, the single gene analysis-based or PCR-based sequencing is employed for analyzing mutations in particular genes with the help of NGS multiplex testing.
Application Takeaway
The therapy selection for metastatic breast cancer segment is anticipated to witness a considerable growth in the estimated period owing to growing prevalence of metastatic caner all across the globe. It is estimated that liquid biopsy will find application in the molecular monitoring diagnostic, which can be investigated using various biofluids such as saliva, urine, CSF, and blood for patient screening during the forecast period.
Regional Takeaway
Presently, the North America region dominated the global liquid biopsy market in 2018 owing to increasing incidence of cancer and growing need for screening in this region. Europe is estimated to be the second-largest market due to recent regulatory CE approvals for commercial use of liquid biopsy tests.
Key Vendors Takeaway
The major players functioning in the global market are applying several strategies such as mergers & acquisitions and product launches to increase their market share. Some of the prominent players include Guardant Health, Biocept, Personal Genome Diagnostics, Adaptive Biotechnologies, NeoGenomics Laboratories, Cynvenio, Qiagen, RainDance Technologies, and Trovagene.
The market size and forecast for each segment and sub-segments has been considered as below:
¥ Historical Year Ð 2015 to 2018
¥ Base Year Ð 2019
¥ Estimated Year Ð 2020
¥ Projected Year Ð 2026
TARGET AUDIENCE
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LIQUID BIOPSY MARKET KEY PLAYERS
? NeoGenomics Laboratories
? Guardant Health
? Biocept
? Cynvenio
? Qiagen
? RainDance Technologies
? Adaptive Biotechnologies
? Personal Genome Diagnostics
? Trovagene
GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE
? Urine Sample-based
? Blood Sample-based
? Other Biofluids
GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY
? Multi-gene-parallel Analysis (NGS)
? Single Gene Analysis (PCR Microarrays)
GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER
? Circulating Tumor DNA (ctDNA)
? Circulating Tumor Cells (CTC)
? Exosomes
GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION
? Molecular Health Monitoring
? Therapy Selection for Metastatic Breast Cancer (MBS)
? Therapy Selection for Other Metastatic Cancer
GLOBAL LIQUID BIOPSY MARKET, BY REGION
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$3,250

Liquid Biopsy Market

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed